Literature DB >> 3581088

Cell surface properties associated with malignancy of metastatic large cell lymphoma cells.

S S Joshi, P A Tilden, J D Jackson, J G Sharp, K W Brunson.   

Abstract

The highly malignant and metastatic RAW117-H10 cell line was developed by in vivo selection from the Abelson leukemia virus induced parental RAW117-P lymphoma. In this study we have characterized these cell lines with regard to their expression of lymphocyte and macrophage differentiation antigens, adherence, phagocytic properties, binding of various lectins, binding of antibodies to glycolipid asialo-monoganglioside, and the role of butanol extractable cell surface molecules to determine if any of these cell surface properties are associated with the malignant potential of RAW117-H10 cells. The only major difference in immunological phenotypes between RAW117-P and RAW117-H10 cells was an increased expression of Thy-1 molecules by the latter. However, the highly malignant RAW117-H10 cells bound significantly less concanavalin A, Ricinia communis agglutinin, succinylated wheat germ agglutinin, and particularly anti-asialomonoganglioside than their parental counterpart and were resistant to natural killer cell mediated cytolysis. Removal of butanol extractable cell surface molecules significantly decreased the malignancy of RAW117-H10 cells and increased their susceptibility to natural killer cell mediated cytolysis. The butanol treated RAW117-H10 cells regained high in vivo malignancy when recultured for 3 days to permit regeneration of their cell surface components. The butanol extracted RAW117-H10 cells still expressed high levels of Thy-1 indicating that this most probably represented "inappropriate" antigen expression. Since the expression of lymphocyte differentiation antigens did not correlate with the malignant behavior of the cells, we postulate that these antigenic differences merely represent phenotypic variation. The decreased malignant potential of the butanol treated RAW117-H10 cells did correlate with increased cell surface anti-asialomonoganglioside binding (glycolipid) and increased natural killer cell susceptibility.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581088

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Effect of hyperthermia and thermochemotherapy on primary and metastatic tumour cells of AKR lymphoma.

Authors:  G Klorin; A Siegal; B Bar-Shira-Maymon; O Klein; J Leibovici
Journal:  Int J Exp Pathol       Date:  1990-08       Impact factor: 1.925

2.  Differential sensitivity to hyperthermia of the F1 and F10 B16 melanoma variants.

Authors:  J Leibovici; G Klorin; M Huszar; S Hoenig; M Michowitz
Journal:  Int J Exp Pathol       Date:  1991-04       Impact factor: 1.925

3.  Enhanced antiproliferative activity by metastatic RAW117 lymphoma cells.

Authors:  S S Joshi; S J O'Connor; D D Weisenburger; J G Sharp; H M Gharpure; K W Brunson
Journal:  Clin Exp Metastasis       Date:  1991 Jan-Feb       Impact factor: 5.150

4.  In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma.

Authors:  D J Verbik; W W Stinson; M J Brunda; A Kessinger; S S Joshi
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

5.  Characterization of metastasis-associated antigens on RAW117 lymphosarcoma cell lines.

Authors:  S S Joshi; J G Sharp; H M Gharpure; K W Brunson
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

6.  Selection for enhanced adhesion to microvessel endothelial cells or resistance to interferon-gamma modulates the metastatic potential of murine RAW117 large-cell lymphoma cells.

Authors:  R A LaBiche; R J Tressler; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1993-11       Impact factor: 5.150

7.  Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts.

Authors:  L Kopper; A Bankfalvi; R Mihalik; T T Glant; J Timar
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 8.  Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

9.  Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice.

Authors:  S S Joshi; L J Messbarger; W Hao
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

10.  Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis.

Authors:  J Hamada; P G Cavanaugh; O Lotan; G L Nicolson
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.